ES2091928T3 - Metodos de prevencion de la replicacion virica. - Google Patents

Metodos de prevencion de la replicacion virica.

Info

Publication number
ES2091928T3
ES2091928T3 ES91909315T ES91909315T ES2091928T3 ES 2091928 T3 ES2091928 T3 ES 2091928T3 ES 91909315 T ES91909315 T ES 91909315T ES 91909315 T ES91909315 T ES 91909315T ES 2091928 T3 ES2091928 T3 ES 2091928T3
Authority
ES
Spain
Prior art keywords
viral replication
prevention methods
replication
viral
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91909315T
Other languages
English (en)
Inventor
Hubert E Blum
Tsanyang Liang
Eithan Galun
Jack R Wands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24034871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2091928(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2091928T3 publication Critical patent/ES2091928T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10161—Methods of inactivation or attenuation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cookers (AREA)
  • Cold Cathode And The Manufacture (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A METODOS Y COMPUESTOS PARA INHIBIR LA REPRODUCCION VIRAL. EN PARTICULAR, SE CONSIGUE LA FINALIZACION COMPLETA E IRREVERSIBLE DE LA REPRODUCCION DE UN VIRUS MEDIANTE LA INTRODUCCION DE AL MENOS UNA MUTACION EN ZONAS ESPECIFICAS EN EL GEN DE LA POLIMERASA VIRAL. EL METODO PUEDE UTILIZARSE PARA EVITAR O TRATAR INFECCIONES VIRICAS.
ES91909315T 1990-04-20 1991-04-22 Metodos de prevencion de la replicacion virica. Expired - Lifetime ES2091928T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51142890A 1990-04-20 1990-04-20

Publications (1)

Publication Number Publication Date
ES2091928T3 true ES2091928T3 (es) 1996-11-16

Family

ID=24034871

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91909315T Expired - Lifetime ES2091928T3 (es) 1990-04-20 1991-04-22 Metodos de prevencion de la replicacion virica.

Country Status (10)

Country Link
EP (1) EP0528903B1 (es)
JP (1) JPH05506993A (es)
AT (1) ATE142690T1 (es)
AU (1) AU656136B2 (es)
CA (1) CA2081022A1 (es)
DE (1) DE69122098T2 (es)
DK (1) DK0528903T3 (es)
ES (1) ES2091928T3 (es)
GR (1) GR3021656T3 (es)
WO (1) WO1991016420A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633449A (en) * 1990-03-12 1997-05-27 Cornell Research Foundation, Inc. Induction of resistance to viral diseases in plants
US5596132A (en) * 1990-03-12 1997-01-21 Cornell Research Foundation, Inc. Induction of resistance to virus diseases by transformation of plants with a portion of a plant virus genome involving a read-through replicase gene
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
GB9208545D0 (en) * 1992-04-21 1992-06-03 Gatsby Charitable Foundation T Virus resistant plants
WO1993025068A1 (en) * 1992-06-08 1993-12-23 Cornell Research Foundation, Inc. Viral resistance by plant transformation with a replicase portion of a plant virus genome
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
DE19517532C2 (de) 1995-05-12 1999-10-28 Max Planck Gesellschaft HBV-Vektoren und Zellen zu ihrer Bereitstellung
CN100412190C (zh) * 2001-03-15 2008-08-20 复旦大学 乙肝病毒全基因组多聚酶嵌合体的组建方法和应用
CN102643858B (zh) * 2011-02-16 2014-04-02 复旦大学 一种高效复制的人乙型肝炎病毒重组载体及其应用
EP3505528B1 (en) 2011-04-21 2020-11-25 Ionis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650756T2 (de) * 1985-03-21 2001-10-04 Cornell Res Foundation Inc Vom parasit abgeleiteter widerstand
AU4315689A (en) * 1988-08-16 1990-03-23 Fox Chase Cancer Center Defective hepadnaviruses and producer cell line for vaccines and treatment of liver diseases and disorders
NZ244820A (en) * 1991-10-25 1994-01-26 Isis Pharmaceuticals Inc Oligonucleotide inhibitor of epstein-barr virus.

Also Published As

Publication number Publication date
WO1991016420A1 (en) 1991-10-31
DE69122098T2 (de) 1997-02-20
GR3021656T3 (en) 1997-02-28
DE69122098D1 (de) 1996-10-17
CA2081022A1 (en) 1991-10-21
DK0528903T3 (da) 1996-09-30
ATE142690T1 (de) 1996-09-15
AU656136B2 (en) 1995-01-27
JPH05506993A (ja) 1993-10-14
EP0528903B1 (en) 1996-09-11
AU7785891A (en) 1991-11-11
EP0528903A1 (en) 1993-03-03
EP0528903A4 (en) 1993-09-08

Similar Documents

Publication Publication Date Title
ES2091928T3 (es) Metodos de prevencion de la replicacion virica.
AU6125296A (en) Oligonucleotides specific for hepatitis b virus
NO963860L (no) Isoprenyl-transferase-inhibitorer
NO20005839D0 (no) Preparater for behandling av HIV og andre virale infeksjoner
NO954217L (no) Guanosinrike antivirus-oligonukleotider
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
NO942056D0 (no) Fremgangsmåte ved polymerisering av C4-40- og med andre
DE3884200T2 (de) Verfahren zur Behandlung von Mastitis und anderen Staphylokokkeninfektionen.
PT98565A (pt) Um processo de producao de uma composicao para o tratamento da infeccao por hsv
ES2125976T3 (es) Otros derivados de indol con accion antiviral.
ATE173466T1 (de) Verbindungen und methoden zur inhibition von hiv und verwandten viren
BR9814432A (pt) Composições derivadas de mycobacterium vaccae e processo para seu uso
DE69230643T2 (de) Methode zur behandlung von viralen infektionen
ATE273011T1 (de) Zusammensetzung und verfahren zur behandlung von herpes simplex
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
DE3765137D1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von virus-infektionen.
PT87004A (pt) Process for the preparation of compositions for the treatment of viral infections and composites 3'-azide-2',3'-didesoxy-in osine and 3'-fluoro-2',3'-didesoxyguanosine
WO1996039500A3 (en) Oligonucleotides specific for hepatitis c virus
ES2014042A6 (es) Un procedimiento para la preparacion de una composicion de 1-(2'-desoxi -2' fluor -b- d- arabinofuranosil) -5-etiluracilo.
HUT44439A (en) Process for inhibiting the reproduction of viruses and virus infections
AU2396900A (en) Treatment and prevention of hiv and other viral infections
TW223019B (es)
MD950289A (en) Process for uranil ions recovery out of sewage
FR2702490B1 (fr) Procédé de lyophilisation de cultures de microorganismes, lyophilisats obtenus et leur utilisation.
ATE56878T1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von virus-infektionen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 528903

Country of ref document: ES